TAILIEUCHUNG - Báo cáo y học: " Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa | Wang et al. Virology Journal 2011 8 28 http content 8 1 28 J VIROLOGY JOURNAL RESEARCH Open Access Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa Shaoyang Wang Dedong Huang Shunlai Sun Weimin Ma Qin Zhen Abstract In order to examine whether variation in interleukin-10 promoter polymorphism would predict the likelihood of sustain response of chronic hepatitis B to treatment with interferon alfa IFN-a the inheritance of 3 biallelic polymorphisms in the IL-10 gene promoter in patients with 52 chronic hepatitis B were determined by polymerase chain reaction PCR -bared techniques restriction enzyme digestion or direct sequencing. The relationship to the outcome of antiviral therapy for chronic HBV infection was studied in 24 patients who had a virologically sustained response SR and in 28 non-responder NR to interferon alfa-2b and several IL-10 variants were more frequent among SR compared with NR. Carriage of the -592A allele -592A A genotype and -1082 -1819 -592 ATA haplotype was associated with SR. Our findings indicate that heterogeneity in the promoter region of the IL-10 gene has a role in determining the initial response of chronic hepatitis B to IFN-a therapy. Introduction Hepatitis B is a worldwide disease and remains a significant etiology of chronic hepatitis cirrhosis and hepatocellular carcinoma especially in several areas of Asia and Africa 1 . It is estimated to affect over 350 million people worldwide with a mortality of over million deaths per year because of acute or chronic hepatitis B infection 2 3 . For active hepatitis B patients with detectable hepatitis B virus e antigen HBeAg or hepatitis B virus HBV DNA and elevated alanine aminotransferase ALT serum levels treatment is often recommended. Six-month course of interferon alfa IFN-a therapy has been shown to induce a long-term sustained remission in 25 to 40 of chronic hepatitis B patients 1 4 5 . However the question

TÀI LIỆU LIÊN QUAN
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.